icobrain

icobrain is software designed to automate the volumetric quantification of brain structures from MR images using T1-weighted and FLAIR sequences, employing distinct pipelines for single timepoint analysis and longitudinal change detection. Its methodology relies on DICOM image processing, probabilistic atlas-based segmentation, and statistical comparison to normative data for certain brain volumes, demonstrating high correlation with ground truth in performance tests across various neurological conditions.

icobrain is medical image processing software designed for the automatic labeling, visualization, and volumetric quantification of segmentable brain structures from MR images. It aims to automate the traditionally manual process of identifying, labeling, and measuring the volume of these structures. The software processes T1-weighted and fluid-attenuated inversion recovery (FLAIR) DICOM MR images. It features two distinct image processing pipelines: 'icobrain cross' for analyzing images from a single timepoint, and 'icobrain long' for assessing changes in volumes between two images acquired at different timepoints using the same scanner and protocol; the results from these two pipelines are not interchangeable. The system first detects the scan type and converts images from DICOM to NIFTI format. It then performs segmentation to calculate brain structure volumes, and if applicable, changes in these volumes over time. Outputs include an electronic report with volumetric data and segmentations overlaid on the input images. Key measures provided are normalized volumes and volume changes for the whole brain and grey matter (corrected for head size and compared to a healthy population via a statistical model), and unnormalized volumes and changes for FLAIR white matter hyperintensities. The underlying technology involves skull stripping, brain segmentation based on a probabilistic atlas and image intensity, and volume calculations. Performance testing on 349 diverse subject datasets (including healthy individuals, and patients with Alzheimer’s disease, multiple sclerosis, traumatic brain injury, and depression) demonstrated high accuracy and reproducibility, with an average Pearson correlation coefficient of 0.90 and an intraclass correlation coefficient of 0.89 against ground truth or test-retest data.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How robust is the 'icobrain long' pipeline to variations in MRI scanner hardware and acquisition parameters when assessing longitudinal changes, even if the protocol is nominally "the same"?; What is the clinical utility and impact on diagnostic confidence of the normalized whole brain/grey matter volumes when compared to the healthy population, particularly for early or subtle pathological changes?; Given that FLAIR white matter hyperintensity volumes are unnormalized, what are the recommended best practices for interpreting their changes over time in clinical or research settings?; What are the known limitations of the probabilistic atlas used by icobrain, especially concerning its applicability across diverse patient populations (e.g., different age groups, ethnicities, or rare conditions)?; How sensitive is icobrain's segmentation and volumetric output to common MRI artifacts (e.g., motion, susceptibility) and what pre-processing steps are in place to mitigate their impact?